Phase 1 of Admedus HSV-2 trial achieves primary endpoint
03 February, 2014Admedus (ASX:AHX) has announced interim study results on its phase 1 trial of a therapeutic vaccine for herpes simplex virus (HSV-2).
Mesoblast's MPCs reduce back pain in phase II trial
30 January, 2014 by Dylan Bushell-EmblingPatients with low back pain from early disc degeneration treated with Mesoblast (ASX:MSB) MPCs during a phase II trial reported reduced back pain and required fewer pain drugs compared to controls.
Medtech event of the year open for registration
30 January, 2014The annual AusMedtech national conference will again be held in Melbourne, from 1-2 April at the Hilton on the Park. The flagship medical technology event of the year has just confirmed Mick Farrell, CEO of ResMed, to speak on day one.
Calzada scores licence deal for AOD9604
28 January, 2014 by Dylan Bushell-EmblingCalzada (ASX:CZD) subsidiary Metabolic has secured the first of what it hopes will be a number of licensing agreements with Australian compounding pharmacies for its peptide drug AOD9604.
IDT Australia weighing acquiring HRT product
28 January, 2014 by Dylan Bushell-EmblingIDT Australia (ASX:IDT) is evaluating acquiring Perrigo's US ANDA filing for a synthetic oestrogen product, as it seeks to expand its specialty generic drug portfolio.
Annual CEO industry survey to check the 'pulse' of the Australian industry
28 January, 2014AusBiotech calls on industry leaders (CEOs and MDs) to respond to the annual Biotechnology Industry Position Survey 2014 in order to contribute to the annual snapshot and build the advocacy platform for the year to come.
Cochlear facing $150m penalty from patent case
24 January, 2014 by Dylan Bushell-EmblingA US jury has found Cochlear (ASX:COH) liable of patent infringement and awarded damages of US$131.2m, but the company has vowed to appeal.
iSonea products recognised at CES
23 January, 2014 by Dylan Bushell-EmblingiSonea (ASX:ISN) has picked up a Tech Podcast Network award for its asthma symptom monitoring tools AirSonea and AsthmaSense Prime.
Immuron to raise $9.6m in rights issue
23 January, 2014 by Dylan Bushell-EmblingImmuron (ASX:IMC) has commenced a $9.6m capital raising, for purposes including raising funds for upcoming phase IIb trial of IMM-124E in NASH.
Review resumes on employee share schemes for start-ups
23 January, 2014The federal government has resumed a review on Employee Share Schemes that had paused pre-election when the government entered caretaker mode. Submissions that were lodged previously with the government will be considered as part of this consultation process and new submissions will be accepted now.
Regeneus lines up manufacturer for US CryoShot trial
22 January, 2014 by Dylan Bushell-EmblingGlobal stem cell manufacturer Lonza has agreed to produce the stocks of Regeneus' (ASX:RGS) cell therapy CryoShot Canine for an upcoming US marketing study.
Phosphagenics in for Indian royalties from TPM gels
21 January, 2014 by Dylan Bushell-EmblingPhosphagenics' (ASX:POH) Indian partner Themis and Novartis are both launching into the Indian market diclofenac gel products which use Phosphagenics' TPM drug-delivery technology.
Economic industry reviews for Vic and SA to inform manufacturing transition
21 January, 2014In a call for submissions, federal Industry Minister Ian Macfarlane has announced reviews for Victoria and South Australia to guide Australia's transition to "a new era of manufacturing and competitiveness" in preparation for the departure of Ford and Holden's manufacturing.
First UK NHS patient treated with Iluvien: pSivida
17 January, 2014 by Dylan Bushell-EmblingpSivida (ASX:PVA) licensee Alimera Sciences has announced that the first UK NHS patient has been implanted with its Iluvien diabetic macular edema (DME) treatment.
China's first free trade zone tipped to open access to investors
16 January, 2014China's piloting of its first free trade zone (FTZ) in Shanghai is drawing interest from Australian business, following its launch in late 2013. Backed by Chinese Premier Li Keqiang, the FTZ is expected to be a testing ground for a number of economic reforms, with its tax-free period of 10 years for businesses and the permitting of yuan convertibility and unrestricted foreign currency exchange in the area.
